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Objective: The aim of this study was to investigate the predictive factors of prostate volume (PV) by
analyzing potential predictors in a population of middle-aged men with bothersome lower urinary tract
symptoms (LUTS) and use a prediction model for PV estimation to compare with digital rectal exami-
nation (DRE) alone.
Materials and methods: Patients between the ages of 40 years and 64 years who underwent transrectal
prostate ultrasound as part of a self-paid medical check-up were enrolled. Participant demographics,
medical history, and voiding symptoms were assessed by the International Prostate Symptoms Score
(IPSS) questionnaire. A multiple linear regression with stepwise selection was used to analyze the cor-
relations between PV and all potential predictors.
Results: Two hundred and twenty-eight men with bothersome LUTS (IPSS > 7) were enrolled as study
participants at a mean age of 56.4 years. Patients with PV > 25 mL were signiﬁcantly older and had
higher serum prostate-speciﬁc antigen (PSA) levels and scores for total IPSS, storage, urgency items, and
nocturia items. DRE, serum PSA, age, and urgency score were independent predictors for PV, especially
for men with PV > 25 mL, for which the standardized regression equation was PV ¼ 0.74  (DRE
estimation) þ 0.10  (age) þ 0.12  (serum PSA) þ 0.079  (urgency score) (adjusted R2 ¼ 0.80).
Conclusion: In the current study, we conﬁrmed that serum PSA, age, and urgency score are signiﬁcant
predictors of PV. The prediction model including DRE, PSA, age, and urgency score was a better method
to estimate PV than DRE alone, especially for men with a larger prostate (PV > 25 mL).
Copyright © 2014, Taiwan Urological Association. Published by Elsevier Taiwan LLC. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Middle-aged men often experience lower urinary tract symp-
toms (LUTS) secondary to benign prostatic hyperplasia (BPH).1,2
Prostate volume (PV) estimation has become increasingly impor-
tant, because of the association between PV, LUTS, BPH progression,
and the need for surgery.3e5 Moreover, PV estimation may help in
predicting treatment response and selecting therapeutic options.5,6
Transrectal prostate ultrasound (TRUS) was a validated tool for PV
estimation,7 but its invasiveness and costs limited the role of this
procedure in a primary clinical setting.rtment of Surgery, Cardinal-
ing Street, Yonghe District,
).
rk.
ociation. Published by Elsevier TaDespite the development of sizing scales and three-dimensional
relief models to accurately determine PV,7 digital rectal examina-
tion (DRE) may underestimate PV,8 and the correlation between
DRE and TRUS in estimating PV has not been well established in
previous studies.
Past research indicated that age and body weight, along with
PSA, ﬁt a prediction model for PV.9 In this study, we aim to inves-
tigate the predictive factors of PV by analyzing potential covariates
in a population of middle-aged men with signiﬁcant LUTS, and use
a prediction model for PV estimation compared to DRE alone.
2. Materials and methods
During January 2010 through to December of 2010, we consec-
utively enrolled patients age 40 years or older (40e64 years) who
underwent transrectal ultrasound as part of a medical checkup at a
single institute. Because the study group consisted of men whoiwan LLC. This is an open access article under the CC BY-NC-ND license (http://
Table 1
Demographic characteristics of study participants (N ¼ 228).
Mean ± SD (range)
Age (y) 56.4 ± 7.30 (40e64)
Body height (cm) 170 ± 5.72 (152e188)
Body weight (kg) 72.1 ± 9.79 (47.7e100)
Prostate volume (mL) 32.2 ± 14.1 (4.7e86.3)
Serum PSA (ng/dL) 1.56 ± 1.69 (0.13e11.3)
IPSS
Total 14.1 ± 5.22 (8e32)
QoL score 3.26 ± 1.08 (1e6)
Storage score 5.50 ± 2.57 (0e13)
Frequency 2.64 ± 1.37 (0e5)
Urgency 1.29 ± 1.28 (0e5)
Nocturia 1.57 ± 1.02 (0e5)
Voiding score 8.60 ± 4.06 (0e20)
Incomplete emptying 2.54 ± 1.50 (0e5)
Intermittency 2.23 ± 1.52 (0e5)
Weak stream 2.46 ± 1.70 (0e5)
Straining 1.36 ± 1.38 (0e5)
DRE (n, %)
Prostate size estimation
<20 mL 41 (18.0)
20e30 mL 86 (37.7)
30e40 mL 67 (29.4)
40e50 mL 20 (8.8)
>50 mL 14 (6.1)
Palpation ﬁndings
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all patients. Participant demographic characteristics, clinical
symptoms, and medical histories were collected. Individuals were
excluded if they had a history of prostate cancer or prostate surgery
or were currently using medication known to interfere with void-
ing symptoms. Two hundred and twenty-eight men with bother-
some LUTS [International Prostate Symptoms Score (IPSS)> 7] were
enrolled after they completed the validated Chinese version of the
IPSS questionnaire, and maximum ﬂow rate (Qmax) was assessed.
Experienced urologists performed DRE with the ball scale or
three-dimensional relief model, consisting of a board with several
rubbery 0.5-cm-high models representing different PVs, to esti-
mate PV in increments of 10 g. In addition, the shape, symmetry,
ﬁrmness, and nodularity of the prostate were assessed.
PV was measured by one of the experienced urologists, mainly
senior residents, using the LOGIQ P5 TRUS system (GE Healthcare,
Milwaukee, WI, USA). The area of greatest transverse diameter in
the transverse view, and anteroposterior and transverse di-
mensions of the prostate were measured. Sagittal scanning was
subsequently performed, and the distance from the base to the
apex in the median plane was measured along the longitudinal
dimension. The formula anteroposterior dimension  transverse
dimension  longitudinal dimension  p/6 was used for the
calculation PV on TRUS.10Benign 219 (96.1)
Asymmetry 2 (0.9)
Focal hardness 7 (3.1)
Nodularity 0
Qmax < 15 mL/s 98 (43.0)
Metabolic proﬁles
BMI (kg/m2) 25.0 ± 2.73 (18.4e32.2)
Waist circumference (cm) 89.8 ± 7.38 (70e111)
Presence of metabolic syndrome 49 (21.5)
Presence of hypertension 102 (44.7)
Serum glucose AC 96.0 ± 17.3 (75e243)
Serum HbA1C 5.77 ± 0.64 (4.4e10.2)
Serum triglyceride 124 ± 67.0 (23e564)
Serum cholesterol (mg/dl) 198 ± 32.9 (116e278)
Serum HDL cholesterol (mg/dl) 46.0 ± 10.1 (26e83)
Numeric data are expressed as mean ± SD (range) and categorical data are
expressed as n (%).
BMI ¼ body mass index; DRE ¼ digital rectal examination; HDL ¼ high-density li-
poprotein; IPSS ¼ International Prostate Symptom Score; PSA ¼ prostate-speciﬁc
antigen; SD ¼ standard deviation.2.1. Statistical analysis
Continuous variables were analyzed with the Student t test and
are presented as mean ± standard deviation (SD). Categorical var-
iables were analyzed with the Chi-square test and were recorded as
frequencies or percentages. The two-sided alpha level was 0.05. A p
value of <0.05 was considered to be statistically signiﬁcant.
Multiple linear regression analysis was used to examine the
association between PV and potential predictors. Categorical vari-
ables, such as DRE, were modeled as a series of dummy variables. A
stepwise selection method was chosen for the ﬁnal model. The
analyzed covariates included age, weight, height, body mass index,
DRE estimation, serum PSA levels, the presence of metabolic syn-
drome or hypertension, serum cholesterol levels, serum high-
density lipoprotein levels, fasting blood sugar levels, serum tri-
glyceride levels, waist circumference, total IPSS scores, storage
scores, voiding scores, and IPSS item scores. The Pearson or
Spearman correlation coefﬁcients (r) were used to assess the rela-
tionship between PV and potential predictors. All data in the pre-
sent study were analyzed with a commercial statistical software
package (SPSS version 13.0 for Windows, SPSS Inc., Chicago, IL,
USA).3. Results
Table 1 lists clinical and demographic characteristics of all study
participants. The mean age of study participants was 56.4 years
(range 40e64 years). Mean prostate volumemeasured by TRUSwas
32.2 mL (range 4.7e86.3) and mean serum PSA was 1.56 ng/mL
(range 0.13e11.3). The average total IPSS, storage, and voiding
scores were 14.1 ± 5.22, 5.50 ± 2.57, and 8.60 ± 4.06, respectively.
The percentage of metabolic syndrome among study participants
was 21.5%. Ninety-eight patients (43.0%) had lower ﬂow rate
(Qmax <15 mL/s).
Study participants were further categorized by PV in Table 2.
Compared to the PV  25 mL group, the larger PV group
(PV > 25 mL) had signiﬁcantly higher age and serum PSA level, and
suffered more from total IPSS, storage score, item “urgency” and
“nocturia” score.Table 3 shows potential predictors of PV using stepwise multiple
linear regression analysis. DRE estimation, serum PSA, age, and
“urgency” scorewere signiﬁcantly correlatedwith the PVmeasured
by TRUS (all p < 0.05). The adjusted R2 of DRE for four dummy
variables was 0.01, 0.11, 0.10, and 0.43, respectively, and total
contribution was 0.65. The presence of metabolic syndrome and
components including hypertension, serum high-density choles-
terol, fasting blood sugar, serum triglycerides, and body mass index
were not independent predictors of PV estimation.
Table 4 listed the results of regression model categorized by PV.
Potential predictors including DRE, age, serum PSA and “urgency”
score were included in the model. For the smaller PV group, only
DRE was an independent predictor in the regression model. For PV
>25 mL group, DRE estimation, serum PSA, age, and urgency score
were independent predictors for PV, and the standardized regres-
sion equation was: PV ¼ 0.74  (DRE estimation) þ 0.10 
(age) þ 0.12  (serum PSA) þ 0.079  (urgency score) (adjusted
R2 ¼ 0.80). In the regression model for PV  25 mL group, DRE
estimation was the only independent predictor (adjusted
R2¼ 0.45). Furthermore, the correlation coefﬁcients with PV in DRE
estimated size <20 mL, 20e30 mL, 30e40 mL, >40 mL was 0.041
(p ¼ 0.69), 0.453, 0.397, and 0.588, respectively (all p < 0.001, table
not shown).
Table 3
The results of stepwise multiple regression predicting p for study participants
(adjusted R2 ¼ 0.72).a
R2 contribution Unstandardized
regression
coefﬁcient
Standardized
regression
coefﬁcient
p
DRE estimation
Total 0.65 <0.001
<20 mL 0.01 4.38 0.15 0.003
20e30 mL 0.11 11.9 0.39 <0.001
30e40 mL 0.10 20.8 0.42 <0.001
>40 mL 0.43 39.4 0.67 <0.001
Age 0.028 0.28 0.14 <0.001
Serum PSA 0.037 1.43 0.17 <0.001
Urgency score 0.016 1.25 0.11 0.002
DRE ¼ digital rectal examination; PSA ¼ prostate-speciﬁc antigen.
a Covariates included: DRE, age, serum PSA, body height, body weight, body mass
index, waist circumference, serum triglyceride, serum total cholesterol, sugar AC,
serum HbA1C level, total International Prostate Symptom Score, storage scores,
voiding scores, and all subscales.
Table 2
Potential predictors for prostate volume in study participants categorized by pros-
tate volume.
PV > 25 mL PV  25 mL p
Patient number 157 71
Age 57.8 ± 6.65 53.4 ± 7.83 <0.001
Serum PSA 1.87 ± 1.91 0.89 ± 0.65 <0.001
Total IPSS 14.6 ± 5.46 13.0 ± 4.50 0.037
Quality of life 3.24 ± 1.12 3.30 ± 0.98 0.70
Storage score 5.85 ± 2.71 4.73 ± 2.01 0.001
Frequency 2.64 ± 1.35 2.63 ± 1.44 0.96
Urgency 1.53 ± 1.39 0.82 ± 0.87 <0.001
Nocturia 1.70 ± 1.06 1.28 ± 0.85 0.002
Voiding score 8.73 ± 4.25 8.30 ± 3.60 0.45
Incomplete emptying 2.54 ± 1.49 2.54 ± 1.52 0.98
Intermittency 2.29 ± 1.52 2.10 ± 1.52 0.39
Weak stream 2.49 ± 1.71 2.41 ± 1.77 0.74
Straining 1.41 ± 1.42 1.25 ± 1.30 0.42
DRE
Prostate size estimation <0.001
<20 mL 5 36
20e30 mL 58 28
30e40 mL 64 3
40e50 mL 17 3
>50 mL 13 1
Numeric data are expressed as mean ± standard deviation and compared with t test.
Categorical data are expressed as n (%) and compared with Chi-square test.
DRE ¼ digital rectal examination; IPSS ¼ International Prostate Symptom Score;
PSA ¼ prostate-speciﬁc antigen; PV ¼ prostate volume.
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Generally, transrectal ultrasound for PV estimation is well
established as the standard method because of precision and
reproducibility, and European Association of Urology guidelines
have suggested that TRUS is an option for BPH when considering
minimally invasive or surgical interventions.11 Because of itsTable 4
The results of multiple regression predicting prostate volume for study participants cate
PV > 25 mL (N ¼ 157)
R2 contribution Standardized regression coefﬁcient p
DRE 0.77 0.74 <0
Serum PSA 0.020 0.12 0
Age 0.007 0.10 0
Urgency score 0.004 0.079 0
DRE ¼ digital rectal examination; PSA ¼ prostate-speciﬁc antigen; PV ¼ prostate volum
a Covariates included: DRE (dummy variables combined), serum PSA, age, and urgencrelative invasiveness and costs, TRUS may not be available in most
settings, and a more easy and precise method for PV estimation is
required.
DRE is a simple method to estimate PV but with less accuracy. In
the current study, we used stepwise multiple linear regression
analysis to choose the covariates that contribute the most and to
avoid collinearity between covariates in the model. The ﬁnal model
represents that age, serum PSA, and urgency score, along with DRE,
can predict PV better than DRE alone (adjusted R2 ¼ 0.72 vs.
R2¼ 0.65). The general practitioner may use the equation for better
PV prediction than DRE alone.
Previous studies showed that DRE theoretically underestimates
the true PV, and Bosch et al12 indicated that DRE is good only in the
identiﬁcation of a large prostate. In the current study, we conﬁrmed
that the accuracy of DRE to predict PV varied according to different
volume ranges and the prediction model was better ﬁt for the PV
>25 mL group.
Urgency is one of the most annoying symptoms, and may have a
negative inﬂuence on daily work or quality of life for men with
BPH.13 A recent study stated that urgency score is positively
correlated with PV.14 In our model, similarly, there is a signiﬁcant
correlation between urgency score and PV, and menwith larger PV
suffered more from urgency score, which negatively affects quality
of life.
There is emerging evidence that patients with metabolic syn-
drome have an increasing rate of prostate growth, which might
account for the increasing prevalence of LUTS.15 In the general
linear model, the current study showed that none of the metabolic
markers correlated with PV for men with bothersome LUTS, and
larger samples with other statistical methods will be necessary to
clarify the relationships between metabolic markers and PV.
There are several limitations to the study that must be consid-
ered when interpreting the results. First, the current study was a
single-arm analysis without a comparison group; a prospective
study with both arms is necessary to clarify the relationship be-
tween PV and independent predictors such as metabolic syndrome
and markers. Second, DRE was performed by an experienced urol-
ogist and is not representative of all general practitioners or urol-
ogists in clinical settings. Finally, we selected TRUSmeasurement to
represent actual PV. It is known that there are interobserver vari-
ations and controversies in PV estimation by TRUS.16 Terris and
Stamey10 reported on the correlation between TRUS measurement
and prostatic specimen weight, and indicated that the most accu-
rate method varied according to different volume ranges.
5. Conclusion
In the current study, we conﬁrmed that serum PSA, age, and IPSS
item “urgency” score were independent predictors of PV for men
with bothersome LUTS. The prediction model including DRE, PSA,
age, and urgency score was a better method to estimate PV than
DRE alone, especially for patients with a larger prostate
(PV > 25 mL).gorized by prostate volume (adjusted R2 ¼ 0.80 for PV > 25 mL).a
PV  25 mL (N ¼ 71)
R2 contribution Standardized regression coefﬁcient p
.001 0.45 0.65 <0.001
.005 d 0.06 0.30
.009 d 0.09 0.52
.032 d 0.09 0.35
e.
y score.
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